StockData
APUSNYSEPharmaceutical PreparationsFiscal year ends December 31

Apimeds Pharmaceuticals US, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.50−0.54 (-13.37%)

Close on Oct 19, 2026

Market cap
$6.00M
P/E (TTM)
–
Dividend yield
–

Apimeds Pharmaceuticals US, Inc. revenue by segment

No segment breakdown reported

Apimeds Pharmaceuticals US does not break out revenue by segment, region or product in the tagged data of its filings for this period type.